Actively Recruiting
Phase II Study Comparing Elranatamab Plus Daratumumab Versus Autologous Stem Cell Transplant Followed by Lenalidomide and Daratumumab in Newly Diagnosed Multiple Myeloma
Led by SCRI Development Innovations, LLC · Updated on 2026-06-04
100
Participants Needed
11
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating treatments for newly diagnosed multiple myeloma NDMM patients who have completed prior induction therapy. This Phase II open-label, multi-site randomized trial aims to compare two approaches for post-induction consolidation and maintenance therapy elranatamab combined with daratumumab versus autologous stem cell transplant ASCT followed by lenalidomide and daratumumab. The studys primary focus is to assess which treatment better achieves undetectable measurable residual disease MRD in the bone marrow. Participants are randomly assigned to one of two main groups. Arm A receives elranatamab subcutaneously with an initial step-up dosing in the first cycle, followed by weekly dosing, then every two weeks during consolidation cycles, and every four weeks during maintenance cycles, along with daratumumab every four weeks. Arm B undergoes ASCT followed by lenalidomide and daratumumab maintenance treatment. Patients with persistent MRD after maintenance may receive late intensification therapy using the alternative treatment. Treatment cycles are 28 days long, with consolidation and maintenance phases lasting several cycles as described. During the study, participants will undergo regular assessments including MRD testing to monitor disease status, with treatment adjusted based on MRD results. The primary outcome measured is the rate of MRD negativity after completion of the first maintenance phase at 60 weeks. Secondary outcomes include sustained MRD negativity, event-free survival over five years, adverse event rates, and quality of life assessments. Participants remain on therapy until disease progression, discontinuation, death, or completion of planned treatment, with close monitoring throughout the study.
CONDITIONS
Brief Title
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Research Team
S
Sarah Cannon Development Innovations, LLC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here